Studies about Copeptin

Multicentre cross-sectional observational registry to monitor the safety of early discharge after rule-out of acute myocardial infarction by copeptin and troponin: the Pro-Core registry

There is sparse information on the safety of early primary discharge from the emergency department (ED) after rule-out of myocardial infarction in suspected acute coronary syndrome (ACS).
https://bmjopen.bmj.com/content/9/7/e028311.full

Additional Info

  • Indication: Cardiology
  • Authors: Giannitsis E, Clifford P, Slagman A, Ruedelstein R, Liebetrau C, Hamm C, Honnart D, Huber K, Vollert J, Simonelli C, Schröder M, Wiemer J, Mueller-Hennessen M, Schroer H, Kastner K, Möckel M
  • Source: http://dx.doi.org/10.1136/bmjopen-2018-028311
  • Access: Open Access

Arginine-stimulated copeptin measurements in the differential diagnosis of diabetes insipidus: a prospective diagnostic study

Differential diagnosis of diabetes insipidus is challenging. The most reliable approach is hypertonic saline-stimulated copeptin measurements.
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31255-3/fulltext >

Additional Info

  • Indication: Electrolyte Disorders
  • Authors: Winzeler B, Cesana-Nigro N, Refardt J, Vogt D, Imber C, Morin B, Popovic M, Steinmetz M, Sailer C, Szinnai G, Chifu I, Fassnacht M, Christ-Crain M
  • Source: https://doi.org/10.1016/S0140-6736(19)31255-3

EJE AWARD 2019: New diagnostic approaches for patients with polyuria polydipsia syndrome

Diabetes insipidus (DI), be it from central or nephrogenic origin, must be differentiated from secondary forms of hypotonic polyuria such as primary polydipsia. Differentiation is crucial since wrong treatment can have deleterious consequences.
https://eje.bioscientifica.com/view/journals/eje/181/1/EJE-19-0163.xml >

Additional Info

  • Indication: Electrolyte Disorders
  • Authors: Christ-Crain, M
  • Source: https://doi.org/10.1530/EJE-19-0163
  • Access: Open Access

Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease

In the TEMPO 3:4 Trial, treatment with tolvaptan, a vasopressin V2 receptor antagonist, slowed the increase in total kidney volume and decline in estimated glomerular filtration rate (eGFR) in autosomal dominant polycystic kidney disease (ADPKD).
https://www.kidney-international.org/article/S0085-2538(19)30041-9/abstract >

Additional Info

  • Indication: Nephrology
  • Authors: Gansevoort R, van Gastel M, Chapman A, Blais J, Czerwiec F, Higashihara E, Lee J, Ouyang J, Perrone R, Stade K, Torres V, and Devuyst O
  • Source: https://doi.org/10.1016/j.kint.2018.11.044

Cost analysis of early discharge using combined copeptin/cardiac troponin testing versus serial cardiac troponin testing in patients with suspected acute coronary syndrome

The combined copeptin/cTN testing has the potential to save costs and staff time in acute care and for the entire hospital stay. The primary explanations for these findings are early identification and ruling out patients without AMI along with the associated reduced need for acute medical treatment.
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0202133 >

Additional Info

  • Indication: Cardiology
  • Authors: Thomas Reinhold, Evangelos Giannitsis, Martin Moeckel, Lutz Frankenstein, Mehrshad Vafaie, Joern O. Vollert, Anna Slagman
  • Source: https://doi.org/10.1371/journal.pone.0202133
Page 1 of 5

thermo scientific applied biosystems invitrogen fisher scientific unity lab service